Search clinical trials for: CANA/MET XR FDC

Total 88 results

Janssen Research & Development, LLC

Completed

Pharmacokinetics of a Fixed Dose Combination of Canagliflozin/Metformin Coadministered With Food

Healthy Volunteers

United States
Janssen Research & Development, LLC

Completed

Multiple Dose Pharmacokinetics of Canagliflozin/Metformin 150/1,000 mg Fixed Dose Combination

Healthy Volunteers

United States
Janssen Research & Development, LLC

Completed

Effect of Food on a Fixed Dose Combination Tablet of Canagliflozin and Metformin Immediate Release in Healthy Volunteers

Healthy
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Healthy Volunteers

United States
Janssen Research & Development, LLC

Completed

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components

Healthy Volunteers

United States
Janssen Research & Development, LLC

Completed

Bioequivalence Study of Metformin Component of Fixed Dose Combination (FDC) Immediate Release (IR) Tablet of Canagliflozin and Metformin Compared to Metformin IR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Bioequivalence

United States
Elcelyx Therapeutics, Inc.

Completed

Assessing the PK of Met DR, Met IR, and Met XR in Healthy Subjects

Healthy Subjects
Elcelyx Therapeutics, Inc.

Completed

Assessing the Efficacy, Safety, and Tolerability of Met DR in Subjects With T2DM Over 12 Weeks

Type 2 Diabetes Mellitus
Elcelyx Therapeutics, Inc.

Completed

Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction

Renal Insufficiency
Woman's
AstraZeneca

Completed

Dapagliflozin and Metformin,Alone and in Combination, in Overweight/Obese Prior GDM Women (DAPA-GDM)

Diabetes Prevention in Women After GDM Who Are at High-risk

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Healthy

United States
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

Healthy Volunteer

China
Handok Inc.

Completed

A Study to Compare MP-513 20mg & Metformin XR 1000mg FDC With Coadministration of the Two Separate Drugs

Healthy Volunteers

Korea, Republic of
AstraZeneca

Completed

Bioequivalence Study of Combination Tablets of Saxagliptin / Dapagliflozin / Metformin XR (Extended-release) and Dapagliflozin / Metformin XR Relative to Individual Components in Healthy Subjects

Type 2 Diabetes Mellitus

United Kingdom
Janssen Sciences Ireland UC

Completed

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

Immunodeficiency Virus Type 1, Human

United States, France, Poland, United Kingdom, Belgium, Germany, Spain, Canada, Russian Federation, Puerto Rico
AstraZeneca

Completed

Bioequivalence Study of Fixed-dose Combinations and Coadministered Individual Tablets of Saxagliptin/Metformin-Brazil

Type 2 Diabetes Mellitus

Brazil
Shandong Suncadia Medicine Co., Ltd.

Not yet recruiting

A Study to Assess the Bioequivalence of Fixed Dose Combination of HR20033 Relative to Co-administration of the Individual Components in Healthy Chinese Subjects

Type II Diabetes
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Linagliptin/Metformin Extended Release Compared With Single Tablets

Healthy

Germany
Handok Inc.

Completed

A Study to Evaluate the Effect of Food on Fixed-Dose Combination of MP-513 10 mg and Metformin XR 750 mg

Healthy Volunteers

Korea, Republic of
Rowan University

Completed

Trekking Poles to Aid Multiple Sclerosis Gait Impairment (TRAMS)

Multiple Sclerosis

United States
ARKAY Therapeutics
Albany Medical College

Not yet recruiting

Evaluation of Superiority of Valsartan+Celecoxib+Metformin Over Metformin Alone in Type 2 Diabetes Patients (RESILIENCE)

Obesity | Arthritis | Type 2 Diabetes | High Blood Pressure

United States
AstraZeneca

Withdrawn

BE Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin HCl XR Tablet Relative to a 5 mg Saxagliptin (Onglyza™) Tablet and a 500 mg Metformin HCl XR (Glifage® XR Marketed in Brazil by Merck S.A.) Tablet Co-Administered to Healthy Subjects in the Fasted and Fed States

Type 2 Diabetes

Brazil
AstraZeneca

Completed

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

Diabetes Mellitus

United States
Takeda

Completed

Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.

Diabetes Mellitus

United States, Chile, Mexico, Puerto Rico
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
AstraZeneca

Terminated

Study of Saxagliptin, 5-Hydroxy Saxagliptin, and Metformin Concentrations/Levels in Pediatric Subjects With T2DM

Type 2 Diabetes Mellitus

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
AstraZeneca

Completed

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

Diabetes Mellitus

United States
Janssen Research & Development, LLC

Completed

A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participants

Healthy

United States
National Cancer Institute (NCI)

Terminated

ACTOplus Met XR in Treating Patients With Stage I-IV Oral Cavity or Oropharynx Cancer Undergoing Definitive Treatment

Stage IVA Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage IVB Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7 | Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oral Cavity Squamous Cell Carcinoma... and other conditions

United States
Tocagen Inc.

Completed

Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor

Glioblastoma Multiforme | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Tocagen Inc.

Completed

Study of a Retroviral Replicating Vector Combined With a Prodrug to Treat Patients Undergoing Surgery for a Recurrent Malignant Brain Tumor

Glioblastoma Multiforme | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
Washington University School of Medicine
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); N... and other collaborators

Terminated

Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency (CBZ)

Liver Cirrhosis | Alpha-1-antitrypsin Deficiency

United States
Bo-Hyun Yoon

Withdrawn

Efficacy of Quetiapine XR Versus Divalproex on Clinical Outcome Quality of Sleep and Quality of Life in Bipolar Depression

Bipolar Depression

Korea, Republic of
Tocagen Inc.

Completed

A Study of a Retroviral Replicating Vector Combined With a Prodrug Administered to Patients With Recurrent Malignant Glioma

Glioblastoma | Anaplastic Oligoastrocytoma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma

United States
AstraZeneca

Completed

Efficacy and Safety of Quetiapine Versus Quetiapine Plus Lithium in Bipolar Depression (QUALITY)

Acute Bipolar Depression

Brazil, Mexico, Peru, Turkey, Argentina, Chile, Venezuela, Colombia, Guatemala
University of British Columbia
British Columbia Cancer Agency

Unknown

11C Methionine PET for the Detection of Hyperfunctional Parathyroid Tissues

Primary Hyperparathyroidism

Canada
M.D. Anderson Cancer Center

Withdrawn

Venetoclax and Eprenetapopt for the Treatment of Relapsed of Refractory Mantle Cell Lymphoma

Recurrent Mantle Cell Lymphoma | Refractory Mantle Cell Lymphoma

United States
AstraZeneca

Recruiting

Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

Type 2 Diabetes Mellitus (T2DM)

China
University of Lausanne Hospitals
George Coukos, MD PhD, Head of oncology

Recruiting

68Ga-NODAGA-RGD PET/ CT for Tumoral Neoangiogenesis

Pathological Angiogenesis

Switzerland
GlaxoSmithKline
Quintiles, Inc.

Completed

A PH I Pilot Imaging Study to Evaluate Molecular Imaging Methods in HVs and pSS Pts

Autoimmune Diseases

United Kingdom
University of Melbourne
Merck Sharp & Dohme LLC; The Alfred

Terminated

Combination Latency Reversal With High Dose Disulfiram Plus Vorinostat in HIV-infected Individuals on ART

HIV Infections

Australia
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors

Metastatic Skin Squamous Cell Carcinoma | Metastatic Malignant Neoplasm | Unresectable Malignant Neoplasm | Refractory Malignant Neoplasm | Appendix Adenocarcinoma | Locally Advanced Malignant Neoplasm | Skin Squamous Cell Carcinoma | Locally Advanced Skin Squamous Cell Carcinoma | Metastatic Small... and other conditions

United States
M.D. Anderson Cancer Center

Active, not recruiting

Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer

Recurrent Breast Inflammatory Carcinoma | Stage IV Breast Inflammatory Carcinoma

United States
OHSU Knight Cancer Institute
Genentech, Inc.; Oregon Health and Science University; Servier Pharmaceuticals...

Recruiting

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma | Locally Advanced Pancreatic Adenocarcinoma | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8

United States
AstraZeneca

Completed

Efficacy, Safety and Tolerability of Two Fixed Dose Combinations of Aclidinium Bromide/Formoterol Fumarate, Aclidinium Bromide, Formoterol Fumarate and Placebo for 28-Weeks Treatment in Patients With Moderate to Severe, Stable Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States, Australia, Canada, New Zealand
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLETED)

Type 2 Diabetes Mellitus

3

Subscribe